McKesson's initiative improves patient outcomes through better biomarker testing and targeted therapies in community oncology.
McKesson's Precision Care Companion initiative enhances biomarker testing and targeted therapies in community oncology, improving patient outcomes and cost efficiency.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: